Legal & General Group’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-46,449
| Closed | -$7.99M | – | 3608 |
|
|
2021
Q3 | $7.99M | Buy |
46,449
+8,549
| +23% | +$1.12M | ﹤0.01% | 1291 |
|
|
2021
Q2 | $4.76M | Buy |
37,900
+3,069
| +9% | +$387K | ﹤0.01% | 1555 |
|
|
2021
Q1 | $4.72M | Buy |
34,831
+630
| +2% | +$81.4K | ﹤0.01% | 1580 |
|
|
2020
Q4 | $4.38M | Sell |
34,201
-6,170
| -15% | -$723K | ﹤0.01% | 1525 |
|
|
2020
Q3 | $4.54M | Buy |
40,371
+2,104
| +5% | +$209K | ﹤0.01% | 1378 |
|
|
2020
Q2 | $3.65M | Buy |
38,267
+10,329
| +37% | +$996K | ﹤0.01% | 1457 |
|
|
2020
Q1 | $2.51M | Buy |
27,938
+1,687
| +6% | +$131K | ﹤0.01% | 1473 |
|
|
2019
Q4 | $1.39M | Buy |
26,251
+3,972
| +18% | +$181K | ﹤0.01% | 1945 |
|
|
2019
Q3 | $880K | Buy |
22,279
+3,777
| +20% | +$164K | ﹤0.01% | 2037 |
|
|
2019
Q2 | $760K | Buy |
18,502
+758
| +4% | +$31.4K | ﹤0.01% | 2041 |
|
|
2019
Q1 | $826K | Buy |
17,744
+1,136
| +7% | +$49.9K | ﹤0.01% | 2026 |
|
|
2018
Q4 | $723K | Buy |
16,608
+3,087
| +23% | +$154K | ﹤0.01% | 2007 |
|
|
2018
Q3 | $774K | Sell |
13,521
-44
| -0.3% | -$2.16K | ﹤0.01% | 2020 |
|
|
2018
Q2 | $658K | Sell |
13,565
-889
| -6% | -$32.4K | ﹤0.01% | 2045 |
|
|
2018
Q1 | $565K | Sell |
14,454
-2,502
| -15% | -$106K | ﹤0.01% | 2088 |
|
|
2017
Q4 | $721K | Buy |
16,956
+1,094
| +7% | +$41K | ﹤0.01% | 2006 |
|
|
2017
Q3 | $588K | Buy |
15,862
+5,392
| +51% | +$187K | ﹤0.01% | 2043 |
|
|
2017
Q2 | $318K | Buy |
10,470
+923
| +10% | +$26.7K | ﹤0.01% | 2161 |
|
|
2017
Q1 | $252K | Sell |
9,547
-106
| -1% | -$2.79K | ﹤0.01% | 2190 |
|
|
2016
Q4 | $247K | Buy |
9,653
+5,699
| +144% | +$181K | ﹤0.01% | 2172 |
|
|
2016
Q3 | $144K | Sell |
3,954
-260
| -6% | -$8.61K | ﹤0.01% | 2118 |
|
|
2016
Q2 | $145K | Buy |
4,214
+173
| +4% | +$5.62K | ﹤0.01% | 1901 |
|
|
2016
Q1 | $109K | Buy |
4,041
+1,020
| +34% | +$29.7K | ﹤0.01% | 1997 |
|
|
2015
Q4 | $147K | Hold |
3,021
| – | – | ﹤0.01% | 1881 |
|
|
2015
Q3 | $73K | Hold |
3,021
| – | – | ﹤0.01% | 2228 |
|
|
2015
Q2 | $93K | Hold |
3,021
| – | – | ﹤0.01% | 2162 |
|
|
2015
Q1 | $118K | Hold |
3,021
| – | – | ﹤0.01% | 1930 |
|
|
2014
Q4 | $117K | Sell |
3,021
-248
| -8% | -$8.64K | ﹤0.01% | 1862 |
|
|
2014
Q3 | $97K | Buy |
+3,269
| New | +$92.1K | ﹤0.01% | 1902 |
|
Legal & General Group's XLRN Position: Q4 2021 in Review
Legal & General Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 46,449 shares — an estimated $7.99M sold.
Legal & General Group first reported a position in XLRN in Q3 2014 and held it in 29 quarters. The position peaked at $7.99M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Legal & General Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Legal & General Group sold 46,449 Acceleron Pharma shares in Q4 2021, an estimated $7.99M.
- Legal & General Group first reported a position in Acceleron Pharma in Q3 2014 and held it in 29 quarters.
- Legal & General Group's Acceleron Pharma position peaked at $7.99M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Legal & General Group's 13F filing for Q4 2021, filed 14 Feb 2022.